Compare CRM & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRM | NVO |
|---|---|---|
| Founded | 1999 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.5B | 212.7B |
| IPO Year | 2004 | N/A |
| Metric | CRM | NVO |
|---|---|---|
| Price | $265.95 | $51.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 36 | 11 |
| Target Price | ★ $324.20 | $54.25 |
| AVG Volume (30 Days) | 8.5M | ★ 15.7M |
| Earning Date | 12-03-2025 | 02-04-2026 |
| Dividend Yield | 0.63% | ★ 2.39% |
| EPS Growth | ★ 23.36 | 10.06 |
| EPS | ★ 7.49 | 3.67 |
| Revenue | $40,317,000,000.00 | ★ $49,580,393,058.00 |
| Revenue This Year | $10.58 | $7.25 |
| Revenue Next Year | $11.10 | $0.24 |
| P/E Ratio | $35.55 | ★ $14.04 |
| Revenue Growth | 8.41 | ★ 16.64 |
| 52 Week Low | $221.96 | $43.08 |
| 52 Week High | $367.09 | $93.80 |
| Indicator | CRM | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 65.08 | 56.54 |
| Support Level | $264.71 | $47.59 |
| Resistance Level | $269.11 | $53.63 |
| Average True Range (ATR) | 5.05 | 1.17 |
| MACD | 0.62 | 0.46 |
| Stochastic Oscillator | 81.41 | 63.81 |
Salesforce provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.